When exoskeleton robots possess embodied intelligence, "ChengTian Technology" secures nearly 100 million yuan in Series B financing | Exclusive report from 36Kr

36Kr learned that "Cheng Tian Technology" has completed a nearly 100 million yuan Series B financing, led by Xi Venture Capital, with Hao Yue Capital serving as the exclusive financial advisor.

This round of financing will be mainly used for the R & D iteration of embodied intelligent exoskeleton technology, the R & D and registration of new brain - machine products, the expansion of the production base, and the global market expansion. It aims to promote the application of embodied intelligent exoskeleton wearable robots in the rehabilitation, elderly care, and consumer markets, and accelerate the expansion of domestic and overseas channel networks.

At the beginning of 2022, Wang Tian, the founder of Cheng Tian Technology, said in an interview with 36Kr: "Mechanical exoskeleton robots are just a stage in the development process. In the future, exoskeleton robots will be worn on the body like clothes. 'They will be realized with artificial muscle - type materials instead of the compromise method of motor - pulling wires to solve the problem of limited human mobility. So its biggest application scenario must be in the consumer (C - end) market.'"

However, at that time, the market and users did not have a wide - spread understanding of "exoskeleton robots". Therefore, Cheng Tian Technology chose to develop medical - grade products based on the "rehabilitation treatment" scenario, following the path of "2B first, then 2C".

Now, with the development of embodied intelligence and general artificial intelligence, users have higher expectations for exoskeleton products. Wang Tian believes that it is time to expand from the medical scenario to C - end scenarios such as entertainment, travel, and safety. "The exploration of medical - grade products has improved the exoskeleton technology stack, including motors, drives, numerical control algorithms, and EMC standards. Now, developing consumer - grade products for the C - end is like subtraction for us. Technically, it is easier. The focus is on the market and sales."

It is understood that in 2025, Cheng Tian Technology launched the "EasyGo" power - assisted exoskeleton robot series, targeting consumer scenarios such as elderly assistance in walking and outdoor sports. It uses lightweight carbon fiber materials and a bionic structure to provide walking assistance without a power source, with a price of about 2,500 yuan.

Cheng Tian Technology's consumer - grade walking aid

"Previously, in the research we conducted on the clinical side, after users wore the (rehabilitation scenario) exoskeleton robot products, their endurance, walking speed, and 6 - minute walking distance all improved. In terms of gait, stability and symmetry also increased, which means that the users' risk of falling and walking energy consumption will decrease." Wang Tian introduced. "The products targeting the general consumer (C - end) market have just been launched, and we are currently collecting user feedback. We hope to help the elderly or patients with sequelae of central nervous system diseases expand their living radius."

In the past few years, hospital rehabilitation departments and community rehabilitation centers have been the "main battlefields" for the application of Cheng Tian Technology's exoskeleton robots, mainly for the rehabilitation training of patients with central nervous system diseases (such as stroke hemiplegia, paraplegia, and cerebral palsy). Now, the biological signals it collects and uses to judge "patients' intentions" have also expanded from electromyography and movement postures to electroencephalography and spinal electricity.

"For example, in the past, when the exoskeleton judged the patient's (movement intention), it was more like 'you draw, I guess', with problems such as accuracy deviation and lag. With the improvement of the ability of electrical signal collection and decoding algorithms, we have directly added neural signals such as electroencephalography and spinal electricity to the rehabilitation process. Based on the plasticity of motor nerves, the curative effect of patients' motor recovery is also better." Wang Tian introduced.

Cheng Tian Technology's exoskeleton robot solution, provided by the enterprise

According to the data of Cheng Tian Technology, its medical - grade products have served more than 623,000 users in total. Through the multi - modal biological signal fusion algorithm, it generates dynamic rehabilitation paths for users, making the intention recognition accuracy of rehabilitation exoskeleton robots reach 98.7%, increasing the daily service efficiency of robots by 3 times, and promoting the gait training efficiency of stroke users by about 53%.

In addition, it is exploring a clinical solution for "spinal cord electrical stimulation + exoskeleton" treatment in order to break through the ceiling of the curative effect of rehabilitation treatment for patients with spinal cord injuries.

According to Wang Tian, in addition to the domestic market, in terms of going global, its classic UGO series of rehabilitation exoskeleton products obtained the EU CE certification at the end of 2024 and are gradually expanding the market along the regions of the land and sea "Silk Road".

"The original intention of Cheng Tian Technology to develop robots is to make people live more easily, decently, and with dignity. In the future, everyone may have an exoskeleton robot to accompany and enhance their abilities, just like 'Venom' in superhero movies, appearing when people need it. There will be in - depth integration and symbiosis between humans and machines to prevent AI and robots from replacing or completely disciplining humans."